About Humira

Note: clicking on a link opens a browser window.

Summary of Humira.

Humira, also known as D2E7 and Adalimumab, is a DMARD. It is an anti-tnf (tumor necrosis factor) drug. Tnf is known to play a part in the inflammation and swelling of joints and other tissues associated with rheumatoid arthritis. Humira was developed by Knoll Pharmaceuticals and Cambridge Antibody Technologies Group in Europe. Abbott Laboratories bought Knoll in 2001, and is continuing the work on Humira. As of October of 2002 more than 3500 people have taken Humira in various studies, including FDA-approved studies in the USA. The primary potential side effect of Humira is an increased susceptibility to infection (in fact, you often cannot take Humira if you have a positive tuberculin test). The reports on the web state that about 75% of those with severe rheumatoid arthritis are helped by Humira, and two thirds of those (or about half of all the patients receiving the drug) are markedly helped by Humira. Humira became commercially available in 2003.

My own experience and what I hear from my rheumatologist lead me to believe that Humira is a very good drug for people with RA, and that for me it was better than anything else on the market. On the other hand, I am not a medical doctor.

Websites About Humira (D2E7).


Back to: Arthritis Home
Back to: Dick Shirley's Web Site

Web site by Richard Shirley. Please email suggestions for additional links to